NanoViricides (NYSE:NNVC) Rating Increased to Hold at StockNews.com

NanoViricides (NYSE:NNVC) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

NanoViricides Stock Up 0.3 %

Shares of NanoViricides stock opened at $1.50 on Friday. NanoViricides has a 12-month low of $1.00 and a 12-month high of $3.59. The stock has a market capitalization of $20.86 million, a P/E ratio of -2.14 and a beta of 0.94. The company has a 50-day simple moving average of $1.61 and a 200 day simple moving average of $1.79.

NanoViricides (NYSE:NNVC) last posted its quarterly earnings data on Friday, September 27th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01.

Institutional Trading of NanoViricides

A hedge fund recently bought a new stake in NanoViricides stock. Moss Adams Wealth Advisors LLC acquired a new position in shares of NanoViricides, Inc. (NYSE:NNVC) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,000 shares of the company’s stock, valued at approximately $26,000. Moss Adams Wealth Advisors LLC owned about 0.13% of NanoViricides as of its most recent SEC filing. 10.30% of the stock is currently owned by institutional investors.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.